Bioinformatic evidence from a transcriptional study suggests that MYEOV is upregulated in PDAC and associated with poor clinical outcomes, which can be attributed to the facilitation of glycolysis of tumor cells in PDAC 37. Here, MYEOV is linked to neoplasm.